



OPEN ACCESS

EDITED AND REVIEWED BY
Nicholas M. Barnes,
University of Birmingham,
United Kingdom

*CORRESPONDENCE
Nadezhda A. German,
✉ nadezhda.german@ttuhsc.edu

RECEIVED 23 October 2023
ACCEPTED 25 October 2023
PUBLISHED 01 November 2023

CITATION
German NA (2023), Editorial: Novel
therapeutic approaches to treat
neuroinflammation in the central
nervous system.
Front. Pharmacol. 14:1326774.
doi: 10.3389/fphar.2023.1326774

COPYRIGHT
© 2023 German. This is an open-access
article distributed under the terms of the
Creative Commons Attribution License
(CC BY). The use, distribution or
reproduction in other forums is
permitted, provided the original author(s)
and the copyright owner(s) are credited
and that the original publication in this
journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Editorial: Novel therapeutic approaches to treat neuroinflammation in the central nervous system

Nadezhda A. German*

Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, United States

KEYWORDS

neuroinflammation, microglia, depression, e-cigarettes, ketamine, cognitive impairment

Editorial on the Research Topic

Novel therapeutic approaches to treat neuroinflammation in the central nervous system

We are excited to present *Novel Therapeutic Approaches to Treat Neuroinflammation in the CNS* as a Research Topic for Frontiers in Pharmacology. The topic is focused on neuroinflammation as a marker of multiple pathological conditions. Studies on the mechanisms associated with CNS-centered inflammation provide us with the knowledge to design safer and more effective therapeutics for treating various diseases.

Our issue begins with an original research paper by [Hou et al.](#) on the *in vivo* effect of Chinese Dodder seed, a medicinal plant, on the gut-neuroinflammation axis. The study uses a chronic unpredictable stress-induced depression model in mice to assess the effect of plant-derived compounds on multiple markers of inflammation, including proinflammatory cytokines, inflammatory proteins, and microglia activation. The observed anti-inflammatory effects were correlated with the changes in the gut microbiota of treated animals. Finally, [Hou et al.](#) stated the importance of the combination effects of chlorogenic acid and hypericin, the main constituents of this plant extract, on the *in vivo* outcomes.

The interplay between metabolic diseases and immune responses, immunometabolic responses, is a significant factor that defines clinical representation and treatment outcomes for multiple disorders, including diabetes and obesity. Further, microglia activation in animals has been linked with neuronal injury and cognitive impairment, possibly explaining higher risks of cognitive dysfunction in patients with diabetes. [Zhang et al.](#) report the effect of levetiracetam, an antiepileptic drug, on the cognitive function of diabetic rats. Using the streptozotocin-induced diabetes model, the authors observed dose-dependent enhancement of cognitive function and hippocampus morphology of treated rats, as well as inhibition in microglia activation and CNS inflammation levels. This novel work is the first to report the ability of FDA-approved levetiracetam to prevent microglia polarization and induce mitochondrial M2 transformation as part of the cognitive impairment treatment strategy.

In the comprehensive review by a Norway team of scientists, the potential role of ketamine in the treatment of resistant cases of depression disorders has been assessed

from multiple aspects, including neuroinflammation, neurotoxicity, and neurodegeneration. Lullau et al. have shown that multifaceted actions of this polypharmacological CNS agent result in a rapid and potent reduction of depression symptoms, increased stress resilience, and reversal of stress-induced dysfunctions.

Our issue is concluded with the original research article by Archie et al. looking at the bases of postnatal neuroinflammation associated with prenatal e-sig exposure. The data conclusively show high levels of oxidative stress and mitochondrial dysfunction in pups of CD1 mice exposed to the e-cig vapor with 2.4% nicotine. In addition, higher levels of neuronal injury markers were observed in the postnatal brain, linking this publication to the previous work by this research team on the deterioration of motor, learning, and memory function in e-cig-exposed animals. These data warrant extensive studies on the effect of vaping in pregnant women on the levels and longitude of neuronal injury in neonates.

Taken together, the issue of this Research Topic: “*Novel Therapeutic Approaches to Treat Neuroinflammation in the CNS*” provides recent advances in the deconvoluting mechanisms involved in this pathological process and identifying effective therapeutic strategies for the corresponding treatments. We acknowledge the contributions of all authors to make this research volume possible.

Author contributions

NG: Writing–original draft.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.